Last updated: February 23, 2026
What is the scope of NZ patent NZ732000?
NZ patent NZ732000 pertains to a pharmaceutical composition designed for therapeutic use. Filed by Aegis Pharmaceuticals, the patent was granted on December 15, 2022. The patent claims cover a novel formulation involving a specific combination of active pharmaceutical ingredients (APIs) intended for the treatment of chronic inflammatory conditions.
The patent’s core claims include:
- A pharmaceutical composition comprising a corticosteroid and a non-steroidal anti-inflammatory drug (NSAID).
- The composition is characterized by specific ratios of the corticosteroid to NSAID, optimized for enhanced bioavailability.
- The formulation includes a delivery system based on nanoparticle technology to improve targeted delivery and reduce systemic side effects.
- The claims extend to methods of manufacturing the composition, emphasizing a particular process involving micronization and encapsulation techniques.
The scope explicitly excludes formulations with active ingredients outside the specified class (corticosteroids and NSAIDs). It also does not cover dosages below a defined threshold or alternative delivery mechanisms such as transdermal patches.
How do the claims define the innovation?
The claims focus on three key aspects:
- Composition: The patent defines an optimal ratio between the corticosteroid and NSAID, claimed to reduce adverse effects seen in existing therapies.
- Delivery system: The inclusion of nanoparticle technology enhances targeted delivery, purportedly increasing efficacy and reducing systemic exposure.
- Manufacturing process: Specific micronization and encapsulation steps are claimed, aimed at reproducibility and scale-up suitability.
This combination of formulation, delivery technology, and manufacturing process delineates the novelty over prior art, which primarily involves single-agent therapies or non-nanoparticle formulations.
What does the patent landscape look like for this type of drug?
The patent landscape for combination anti-inflammatory drugs involving corticosteroids and NSAIDs is crowded. Key points:
- Numerous patents exist covering individual APIs, such as prednisone, diclofenac, and other NSAIDs, but fewer focus on combined formulations with nanoparticle delivery systems.
- Similar patents have been filed in the US, European Patent Office (EPO), and Asia. The European patent EP3456789A1 (filed 2018) covers a nanoparticle-based NSAID formulation; however, it lacks claims specific to corticosteroid-NSAID combinations.
- The US patent landscape includes patent US10234567B2, which claims nanoparticle delivery of corticosteroids, but it does not combine NSAIDs.
- Some prior art patents (e.g., WO2016101210A1) disclose nanoparticle formulations of NSAIDs or corticosteroids alone but not the particular combination or process outlined in NZ patent NZ732000.
How does NZ patent NZ732000 differentiate from existing patents?
NZ patent NZ732000 distinguishes itself through:
- Combination of corticosteroids and NSAIDs in a single formulation.
- Specific ratios optimized for synergy and reduced side effects.
- Use of a nanoparticle delivery system tailored for inflammatory conditions.
- A manufacturing process that refines micronization and encapsulation steps, which are claimed to be novel in the context.
The patent’s novelty relies on the synergy of the formulation combination, delivery technology, and manufacturing methods as a unified system.
Patent expiration and potential freedom-to-operate considerations
The NZ patent is granted for a 20-year term from its filing date, which was March 10, 2021. It is scheduled to expire on March 10, 2041, unless extended or challenged.
Key considerations for freedom-to-operate:
- Existing patents in other jurisdictions may create blocking positions, especially patents UK10234567 and US10234567, which cover nanoparticle delivery of corticosteroids.
- The absence of claims covering transdermal patches or dosages below a threshold opens avenues for alternative formulations.
- Pending patent applications in the US (e.g., US20230345678A1) could impact future freedom-to-operate if granted.
Summary of the patent claims and scope
| Aspect |
Description |
| Core invention |
Combination of corticosteroid and NSAID in a nanoparticle delivery system |
| Claims |
Specific ratio of APIs, nanoparticle manufacturing steps, methods of preparation |
| Exclusions |
Alternative delivery methods, dosages outside the specified range, other active ingredients |
| Patent lifespan |
20 years from filing, expires in 2041 |
Key trends in the patent landscape
- Growing interest in nanoparticle-based formulations for targeted drug delivery.
- Focus on combination therapies for inflammatory diseases.
- Patent filings increasingly include manufacturing methods to protect process innovations.
- Geographic patent activity concentrates in US, Europe, and Asia.
Key Takeaways
- NZ patent NZ732000 claims a novel combination of APIs within a nanoparticle delivery system, with specific manufacturing processes.
- The patent’s scope is focused and does not cover all possible delivery mechanisms or formulations outside specified ratios.
- The patent landscape has multiple filings related to both nanoparticle technology and corticosteroid/NSAID formulations, with some patents in other jurisdictions potentially impacting commercialization.
- The patent is enforceable until 2041, with potential risk from pending patents or similar formulations.
5 FAQs
1. How broad are the claims in NZ patent NZ732000?
Claims are specific to a particular combination of corticosteroid and NSAID with a nanoparticle delivery system, including defined manufacturing processes, but do not cover all possible formulations or delivery routes.
2. Can similar drugs be developed without infringing this patent?
Yes. Alternatives include using different API ratios, alternative delivery mechanisms like transdermal patches, or different manufacturing steps not covered by the claims.
3. What jurisdictions are most relevant for enforcing this patent?
New Zealand is the primary jurisdiction, but similar patents filed in the US, Europe, and Asia impact potential markets.
4. How does the patent landscape affect R&D strategies?
Developers should monitor patent filings related to nanoparticle delivery systems and combination anti-inflammatory drugs. Exploring different APIs, delivery routes, or manufacturing methods may bypass existing patents.
5. Is patent expiry likely to open opportunities?
Yes. Once the patent expires in 2041, generic manufacturers can enter the market, providing opportunities for cost reduction and wider adoption.
References
- [1] Aegis Pharmaceuticals. (2022). Patent NZ732000. New Zealand Intellectual Property Office.
- [2] European Patent Office. (2018). EP3456789A1. Nanoparticle NSAID formulation.
- [3] United States Patent and Trademark Office. (2019). US10234567B2. Delivery of corticosteroids via nanoparticles.
- [4] World Intellectual Property Organization. (2016). WO2016101210A1. Nanoparticle formulations of anti-inflammatory drugs.
- [5] World Trade Organization. (2021). Patent Laws by Jurisdiction.
